Future of pharma R&D requires innovative dosage formulations, industry survey shows

9 October 2012

A survey of 500 pharmaceutical industry influencers reveals that four out of five surveyed (82%) believe innovative dosage form technologies are required to meet the needs of today’s pharmaceutical research and development challenges.

Three-quarters (76%) are actively investigating strategies to improve pharmaceutical products by adding drug delivery functionality, such as patient-centric dosing, combination therapy and controlled release options. And, when asked to rank the top three key drivers of innovative dosage forms, patient safety was the top priority followed by combination therapies and controlled release.

“This survey provides critical insights into R&D needs in terms of dosage innovation and outsourcing decisions today and in the future,” said Nigel Walker, managing director of Nice Insight, a pharmaceutical industry market intelligence company. “This type of understanding is fundamental to interpreting the innovation likely to be required to meet evolving patient-centric dosage needs driven by healthcare trends,” he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology